Generated by AI
Acurx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for difficult-to-treat bacterial infections. Acurx Pharmaceuticals Inc. develops small-molecule therapies designed to target Gram-positive pathogens through a distinct mechanism of action, with its lead candidate ibezapolstat aimed at infections such as Clostridium difficile. The company is also advancing ACX-375C, an antibiotic program intended to address resistant bacteria including MRSA, VRE, and drug-resistant Streptococcus pneumoniae. In addition to its lead and pipeline candidates, Acurx Pharmaceuticals Inc. works on anti-infective therapies for pathogens identified as priority threats by major public health agencies. The company operates in the biopharmaceutical sector, where its research is centered on unmet medical needs in infectious disease treatment and the development of new options for antibiotic-resistant infections.
Website259 Liberty Avenue
Staten Island, NY, 10305
United States
The latest articles about ACXP.
Summary of Apr 16's posts. Generated by AI.
Summary of Mar 19's posts. Generated by AI.
Summary of Mar 19's posts. Generated by AI.
Investors talking about ACXP also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.